JP2002529465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002529465A5 JP2002529465A5 JP2000581024A JP2000581024A JP2002529465A5 JP 2002529465 A5 JP2002529465 A5 JP 2002529465A5 JP 2000581024 A JP2000581024 A JP 2000581024A JP 2000581024 A JP2000581024 A JP 2000581024A JP 2002529465 A5 JP2002529465 A5 JP 2002529465A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- compound according
- alkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 55
- 125000000217 alkyl group Chemical group 0.000 description 15
- -1 alkylidenyl Chemical group 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 229910005965 SO 2 Inorganic materials 0.000 description 8
- 125000003710 aryl alkyl group Chemical group 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19107398A | 1998-11-12 | 1998-11-12 | |
| US09/191,073 | 1998-11-12 | ||
| US37083799A | 1999-08-09 | 1999-08-09 | |
| US09/370,837 | 1999-08-09 | ||
| US40136499A | 1999-09-21 | 1999-09-21 | |
| US09/401,364 | 1999-09-21 | ||
| PCT/US1999/027054 WO2000027846A2 (en) | 1998-11-12 | 1999-11-12 | Crf receptor antagonists and methods relating thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002529465A JP2002529465A (ja) | 2002-09-10 |
| JP2002529465A5 true JP2002529465A5 (https=) | 2006-12-21 |
Family
ID=27392849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000581024A Pending JP2002529465A (ja) | 1998-11-12 | 1999-11-12 | Ｃｒｆレセプターアンタゴニストおよびｃｒｆレセプターアンタゴニストに関する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6514982B1 (https=) |
| EP (1) | EP1129091B1 (https=) |
| JP (1) | JP2002529465A (https=) |
| KR (1) | KR20010080990A (https=) |
| CN (1) | CN1217945C (https=) |
| AT (1) | ATE225349T1 (https=) |
| AU (1) | AU755552B2 (https=) |
| CA (1) | CA2350642A1 (https=) |
| DE (1) | DE69903333T2 (https=) |
| DK (1) | DK1129091T3 (https=) |
| ES (1) | ES2180338T3 (https=) |
| HK (1) | HK1038926B (https=) |
| IL (1) | IL142893A0 (https=) |
| NO (1) | NO20012194L (https=) |
| NZ (1) | NZ510955A (https=) |
| PT (1) | PT1129091E (https=) |
| WO (1) | WO2000027846A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6531475B1 (en) * | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| IL142893A0 (en) * | 1998-11-12 | 2002-04-21 | Neurocrine Biosciences Inc | Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same |
| CA2398956A1 (en) * | 2000-02-14 | 2001-08-16 | Japan Tobacco Inc. | A pharmaceutical composition for prophylaxis or therapy of a postoperative stress |
| WO2001087892A1 (en) * | 2000-05-18 | 2001-11-22 | Neurocrine Biosciences, Inc. | Crf receptor antagonists |
| KR20030060927A (ko) * | 2000-11-03 | 2003-07-16 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | Ｃｒｆ 수용체 길항제 및 이와 관련된 방법 |
| DE60130924T2 (de) | 2000-12-28 | 2008-07-17 | Ono Pharmaceutical Co. Ltd. | Cyclopentaädüpyrazoloä1,5-aüpyrimidin-verbindung als crf-rezeptor antagonist |
| WO2002064592A1 (en) * | 2000-12-28 | 2002-08-22 | Neurocrine Biosciences, Inc. | Tricyclic crf receptor antagonists |
| ES2255610T3 (es) | 2001-04-30 | 2006-07-01 | Glaxo Group Limited | Antagonistas de los receptores de crf. |
| JP2004530702A (ja) * | 2001-05-21 | 2004-10-07 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | Ｃｒｆ受容体アンタゴニストとしてのトリ−およびテトラアザ−アセナフチレン誘導体 |
| GB0117395D0 (en) * | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
| US7273871B2 (en) | 2001-07-17 | 2007-09-25 | Sb Pharmco Puerto Rico Inc. | Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| CN100422186C (zh) | 2003-06-25 | 2008-10-01 | 小野药品工业株式会社 | 吡唑并嘧啶化合物的甲磺酸盐、其结晶及其制备方法 |
| US20060024661A1 (en) * | 2003-07-30 | 2006-02-02 | The Regents Of The University Of California | Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2 |
| CA2535249A1 (en) * | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists |
| ATE388150T1 (de) * | 2003-12-22 | 2008-03-15 | Sb Pharmco Inc | Crf-rezeptorantagonisten und diese betreffende verfahren |
| HRP20130971T1 (hr) | 2004-02-20 | 2013-11-08 | Boehringer Ingelheim International Gmbh | Inhibitori virusne polimeraze |
| WO2005087775A1 (ja) * | 2004-03-15 | 2005-09-22 | Ono Pharmaceutical Co., Ltd. | 三環式複素環化合物およびその化合物を有効成分として含有する医薬組成物 |
| CA2576435A1 (en) * | 2004-08-09 | 2006-03-23 | Research Development Foundation | Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis |
| MX2009008084A (es) | 2007-02-01 | 2009-10-12 | Astrazeneca Ab | Derivados de 5,6,7,8-tetrahidropteridina como inhibidores de hsp90. |
| TW201102390A (en) * | 2009-03-31 | 2011-01-16 | Arqule Inc | Substituted pyrazolo-pyrimidine compounds |
| ES2540964T3 (es) | 2009-06-08 | 2015-07-15 | Takeda Pharmaceutical Company Limited | Compuestos de dihidropirrolonaftiridinona como inhibidores de JAK |
| JP2013516420A (ja) * | 2009-12-30 | 2013-05-13 | アークル インコーポレイテッド | 置換されたピロロ−アミノピリミジン化合物 |
| CN113416191A (zh) * | 2021-04-27 | 2021-09-21 | 西安交通大学 | 一种合成三环骨架2-吡啶酮/2-吡啶亚胺类化合物的方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4605642A (en) | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
| US5013737A (en) * | 1988-02-22 | 1991-05-07 | American Cyanamid Company | 2,4,8-Trisubstituted-3H,6H-1,4,5A,8A-tetraazaacenaphtylene-3,5-(4H)-diones and 2,4-8-trisubstituted-4,5-dihydro-5-thioxo-3H,6H-1,4,5A,8A-tetrazaacenaphthylen-3-ones |
| US4904658A (en) | 1988-04-15 | 1990-02-27 | American Cyanamid Company | Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones |
| US5063245A (en) | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
| FR2692893B1 (fr) | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
| TW336932B (en) | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
| KR100190730B1 (ko) | 1992-12-17 | 1999-06-01 | 디. 제이. 우드, 스피겔 알렌 제이 | 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸 |
| ATE177101T1 (de) * | 1992-12-17 | 1999-03-15 | Pfizer | Pyrrolopyrimidine als crf antagonisten |
| TW370529B (en) | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
| DK0674624T3 (da) | 1992-12-17 | 1999-09-13 | Pfizer | Pyrazoler med CRF-antagonistisk aktivitet |
| RU2153494C2 (ru) | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
| TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| WO1995034563A1 (en) | 1994-06-16 | 1995-12-21 | Pfizer Inc. | Pyrazolo and pyrrolopyridines |
| US6020492A (en) | 1995-05-12 | 2000-02-01 | Neurogen Corporation | Deazapurine derivatives; a new class of CRF1 specific ligands |
| FR2735777B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
| EP0901476A4 (en) | 1996-03-26 | 2001-08-16 | Du Pont Pharm Co | PYRIDINES AND PYRIMIDINES FUSION ARYLOXY AND ARYLTHIO AND DERIVATIVES THEREOF |
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| US6326368B1 (en) | 1996-03-27 | 2001-12-04 | Dupont Pharmaceuticals Company | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof |
| ZA973884B (en) * | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
| HU228962B1 (en) | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo triazines, pharmaceutical compositions containing them and use of the compounds |
| US6492520B1 (en) | 1996-08-06 | 2002-12-10 | Pfizer Inc | Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives |
| TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| IL127566A0 (en) | 1996-08-28 | 1999-10-28 | Pfizer | Substituted 6,5-hetero- bicyclic derivatives |
| US6159980A (en) | 1996-09-16 | 2000-12-12 | Dupont Pharmaceuticals Company | Pyrazinones and triazinones and their derivatives thereof |
| FR2754258B1 (fr) | 1996-10-08 | 1998-12-31 | Sanofi Sa | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
| US5760225A (en) | 1996-11-15 | 1998-06-02 | Neurogen Corporation | Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands |
| US5723608A (en) | 1996-12-31 | 1998-03-03 | Neurogen Corporation | 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| IL142893A0 (en) * | 1998-11-12 | 2002-04-21 | Neurocrine Biosciences Inc | Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same |
-
1999
- 1999-11-12 IL IL14289399A patent/IL142893A0/xx unknown
- 1999-11-12 EP EP99960363A patent/EP1129091B1/en not_active Expired - Lifetime
- 1999-11-12 AT AT99960363T patent/ATE225349T1/de not_active IP Right Cessation
- 1999-11-12 CN CN998131717A patent/CN1217945C/zh not_active Expired - Fee Related
- 1999-11-12 ES ES99960363T patent/ES2180338T3/es not_active Expired - Lifetime
- 1999-11-12 KR KR1020017005924A patent/KR20010080990A/ko not_active Ceased
- 1999-11-12 NZ NZ510955A patent/NZ510955A/xx unknown
- 1999-11-12 AU AU17258/00A patent/AU755552B2/en not_active Ceased
- 1999-11-12 JP JP2000581024A patent/JP2002529465A/ja active Pending
- 1999-11-12 DE DE69903333T patent/DE69903333T2/de not_active Expired - Lifetime
- 1999-11-12 PT PT99960363T patent/PT1129091E/pt unknown
- 1999-11-12 HK HK02100690.1A patent/HK1038926B/en not_active IP Right Cessation
- 1999-11-12 WO PCT/US1999/027054 patent/WO2000027846A2/en not_active Ceased
- 1999-11-12 US US09/439,840 patent/US6514982B1/en not_active Expired - Lifetime
- 1999-11-12 CA CA002350642A patent/CA2350642A1/en not_active Abandoned
- 1999-11-12 DK DK99960363T patent/DK1129091T3/da active
-
2001
- 2001-05-03 NO NO20012194A patent/NO20012194L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002529465A5 (https=) | ||
| JP5702392B2 (ja) | キサンチンオキシダーゼ阻害剤として効果的な新規化合物、その製造方法及びそれを含有する医薬組成物 | |
| AU689623B2 (en) | Distamycin a analogues as antitumour or antiviral agents | |
| JP2007512370A5 (https=) | ||
| JP2008530099A5 (https=) | ||
| JP2005509038A5 (https=) | ||
| JP2010504346A5 (https=) | ||
| RU2010111550A (ru) | 2,3-замещенные индольные производные для лечения вирусных инфекций | |
| JP2012528166A5 (https=) | ||
| JP2005535586A5 (https=) | ||
| JP2007517035A5 (https=) | ||
| JP2007505933A5 (https=) | ||
| JP2013538235A5 (https=) | ||
| JP2003519676A5 (https=) | ||
| JP2006528637A5 (https=) | ||
| JP2006507355A5 (https=) | ||
| JP2021525278A5 (https=) | ||
| JP2002529469A5 (https=) | ||
| CA3055233C (en) | Jak kinase inhibitor and preparation method and use thereof | |
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| JP2001525394A5 (https=) | ||
| RU2006126675A (ru) | Антагонисты crf-рецепторов и способы, относящиеся к ним | |
| JP2024112835A5 (https=) | ||
| JP2011144183A5 (https=) | ||
| JPWO2020033520A5 (https=) |